These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36033108)

  • 1. A Critical Examination of Simulation Pricing and Access Recommendations for Atopic Dermatitis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Critical Examination for the Pricing of Eculizumab and Efgartigimod in Myasthenia Gravis.
    Langley PC
    Innov Pharm; 2021; 12(4):. PubMed ID: 36033123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Impossible QALY and the Denial of Fundamental Measurement: Rejecting the University of Washington Value Assessment of Targeted Immune Modulators (TIMS) in Ulcerative Colitis for the Institute for Clinical and Economic Review (ICER).
    Langley PC
    Innov Pharm; 2020; 11(3):. PubMed ID: 34007634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medicaid Formulary Decisions and the Institute for Clinical and Economic Review: Abandoning Pseudoscience in Imaginary Pharmaceutical Pricing Claims.
    Langley PC
    Innov Pharm; 2021; 12(1):. PubMed ID: 34007677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsense on Stilts - Part 1: The ICER 2020-2023 Value Assessment Framework for Constructing Imaginary Worlds.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More Unnecessary Imaginary Worlds - Part 1: The Institute for Clinical and Economic Review's Evidence Report on Janus Kinase (JAK) Inhibitors in Rheumatoid Arthritis.
    Langley PC
    Innov Pharm; 2020; 11(1):. PubMed ID: 34017631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. To Dream the Impossible Dream: The Commitment by the Institute for Clinical and Economic Review to Rewrite the Axioms of Fundamental Measurement for Hemophilia A and Bladder Cancer Value Claims.
    Langley PC
    Innov Pharm; 2020; 11(4):. PubMed ID: 34007652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. More Unnecessary Imaginary Worlds - Part 4: The ICER Evidence Report for Crizanlizumab, Voxelotor and L-Glutamine for Sickle Cell Disease.
    Langley PC
    Innov Pharm; 2020; 11(2):. PubMed ID: 34007618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Post-Menopausal Quality of Life Claims: Overlooking the Requirements of Normal Science and Fundamental Measurement in ICER'S Cost-Effectiveness Assessment of Fezolinetant for Moderate to Severe Vasomotor Symptoms.
    Langley PC
    Innov Pharm; 2023; 14(1):. PubMed ID: 38035319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Yet another Ersatz World: The ICER Final Evidence Report for Additive Cardiovascular Therapies.
    Langley PC
    Innov Pharm; 2019; 10(4):. PubMed ID: 34007580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD).
    Whalley D; McKenna SP; Dewar AL; Erdman RA; Kohlmann T; Niero M; Cook SA; Crickx B; Herdman MJ; Frech F; Van Assche D
    Br J Dermatol; 2004 Feb; 150(2):274-83. PubMed ID: 14996098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Supping with the Devil: Belief and the Imaginary World of Multiple Myeloma Therapies Invented by the Institute for Clinical and Economic Review.
    Langley PC
    Innov Pharm; 2021; 12(3):. PubMed ID: 35601587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mapping Impossible Utilities: The ICER Report on Tezepelumab for Severe Asthma.
    Langley PC
    Innov Pharm; 2022; 13(2):. PubMed ID: 36654713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nothing to Cheer About: Endorsing  Imaginary Economic Evaluations and Value Claims with CHEERS 22.
    Langley P
    F1000Res; 2022; 11():248. PubMed ID: 35444797
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial.
    Tsianakas A; Luger TA; Radin A
    Br J Dermatol; 2018 Feb; 178(2):406-414. PubMed ID: 28845523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Assessment of quality of life illness in adult patients with atopic dermatitis].
    Villela-Segura U; León-Dorantes G; Mercado-Lara A; Guevara-Sanginés E
    Rev Med Inst Mex Seguro Soc; 2021 Aug; 59(4):306-312. PubMed ID: 35023698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents' quality of life in the treatment of pediatric atopic dermatitis.
    Whalley D; Huels J; McKenna SP; Van Assche D
    Pediatrics; 2002 Dec; 110(6):1133-6. PubMed ID: 12456910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The quality of life of parents of children with atopic dermatitis: interpretation of PIQoL-AD scores.
    Meads DM; McKenna SP; Kahler K
    Qual Life Res; 2005 Dec; 14(10):2235-45. PubMed ID: 16328903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peter Rabbit is a Badger in Disguise: Deconstructing the Belief System of the Institute for Clinical and Economic Review in Health Technology Assessment.
    Langley PC
    Innov Pharm; 2021; 12(2):. PubMed ID: 34345518
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of outcomes and parental effect on Quality-of-Life endpoints in the management of atopic dermatitis.
    Arnold RJ; Donnelly A; Altieri L; Wong KS; Sung J
    Manag Care Interface; 2007 Feb; 20(2):18-23. PubMed ID: 17405577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.